Robeco Institutional Asset Management B.V. Invests $604,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Robeco Institutional Asset Management B.V. bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 32,817 shares of the company's stock, valued at approximately $604,000.

Several other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company's stock worth $221,379,000 after acquiring an additional 136,907 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company's stock valued at $121,936,000 after buying an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC raised its holdings in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company's stock valued at $25,928,000 after buying an additional 1,634,000 shares during the period. Bank of New York Mellon Corp lifted its stake in Hims & Hers Health by 67.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company's stock worth $13,701,000 after acquiring an additional 273,473 shares in the last quarter. Finally, M&G Plc acquired a new position in Hims & Hers Health during the 1st quarter worth about $8,232,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Buying and Selling

In other news, insider Patrick Harrison Carroll sold 15,000 shares of Hims & Hers Health stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $22.07, for a total value of $331,050.00. Following the transaction, the insider now directly owns 196,941 shares of the company's stock, valued at $4,346,487.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the sale, the chief executive officer now directly owns 67,015 shares of the company's stock, valued at approximately $1,399,273.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick Harrison Carroll sold 15,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $22.07, for a total value of $331,050.00. Following the completion of the transaction, the insider now owns 196,941 shares in the company, valued at $4,346,487.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 854,547 shares of company stock worth $15,987,230 in the last quarter. 17.71% of the stock is owned by insiders.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $4.48 during trading on Monday, hitting $27.89. 38,503,416 shares of the company were exchanged, compared to its average volume of 8,820,070. The firm's 50 day moving average price is $18.75 and its 200-day moving average price is $18.49. The stock has a market capitalization of $5.99 billion, a P/E ratio of 62.77 and a beta of 1.06. Hims & Hers Health, Inc. has a 12-month low of $6.68 and a 12-month high of $29.68.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the prior year, the firm posted ($0.04) earnings per share. Hims & Hers Health's revenue for the quarter was up 77.1% on a year-over-year basis. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.25 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on HIMS. Piper Sandler reiterated a "neutral" rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a "buy" rating and a $24.00 target price on the stock. Truist Financial boosted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a "hold" rating in a research note on Thursday, July 18th. Imperial Capital cut Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research note on Friday, August 9th. Finally, Bank of America lifted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the company a "buy" rating in a report on Monday, October 21st. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $21.21.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.